局限期外周T细胞淋巴瘤接受CHOP(类)治疗后的结局:北欧淋巴瘤流行病学组239例基于人群的研究
该研究基于丹麦和瑞典淋巴瘤登记处,纳入2000至2014年确诊并接受CHOP(类)治疗±放疗的239例局限期(I-II期)结节性外周T细胞淋巴瘤成人患者。中位随访127个月,5年总生存率为58%(95%CI:53-65),无进展生存率为53%(95%CI:47-59)。多因素分析显示年龄≥60岁和B症状为不利因素,ALK阳性间变性大细胞T细胞淋巴瘤为有利因素;3-4周期与6-8周期CHOP(类)治疗±放疗的结局无差异。
要点
- 局限期结节性PTCL患者5年OS为58%(95%CI:53-65),PFS为53%(95%CI:47-59)。
- 年龄≥60岁和B症状为不利预后因素,ALK阳性间变性大细胞T细胞淋巴瘤为有利因素。
- 3-4周期与6-8周期CHOP(类)治疗±放疗的结局无差异。
核心结论
- 局限期结节性PTCL接受根治性化疗±放疗后的生存劣于局限期弥漫性大B细胞淋巴瘤,但年轻且无B症状的亚组结局很好。
- 3-4周期与6-8周期CHOP(类)治疗的结局相当。
研究设计与样本
- 基于丹麦和瑞典淋巴瘤登记处的双国家基于人群的研究,纳入2000至2014年确诊的局限期(I-II期)结节性PTCL成人患者,接受CHOP(类)治疗±放疗,医疗记录由当地研究者审查。
- 共纳入239例患者,中位年龄62岁。
主要发现
- 67%的患者接受6-8周期CHOP(类)治疗,22%接受3-4周期,其中59%同时接受放疗;16%的患者接受自体干细胞移植巩固。
- 中位随访127个月,5年OS为58%(95%CI:53-65),5年PFS为53%(95%CI:47-59)。
- 多因素分析中,年龄≥60岁和B症状为不利因素,ALK阳性间变性大细胞T细胞淋巴瘤为有利因素。
- 3-4周期与6-8周期CHOP(类)±放疗的治疗特异性结局无差异。
- 低危患者(年龄<60岁且无B症状)的5年OS为77%(95%CI:67-89)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-Cell Lymphomas (PTCLs) are rare, aggressive lymphomas with poor outcomes, but limited-stage disease is infrequent and not well-described. This study reports outcomes and prognostic factors in limited-stage nodal PTCLs in a binational population-based setting. Patients were identified from the Danish and Swedish lymphoma registries. Adults diagnosed with limited-stage nodal PTCL (stage I-II) and treated with CHOP(-like) therapy ±radiotherapy between 2000 and 2014 were included. Medical records were reviewed by local investigators. A total of 239 patients with a median age of 62 years were included; 67% received 6-8 cycles of CHOP(-like) therapy and 22% received 3-4 cycles, of which 59% also received radiotherapy. Autologous stem cell transplant consolidation was administered to 16% of all patients. Median follow-up was 127 months with 5-years overall survival (OS) of 58% (95% CI: 53-65) and progression-free survival (PFS) of 53% (95% CI: 47-59). In multivariable analysis, age ≥ 60 years and B-symptoms were unfavorable and ALK+ anaplastic large cell T-Cell lymphoma was favorable for survival outcomes. There was no difference in treatment-specific outcome (3-4 cycles vs. 6-8 cycles of CHOP(-like) ± radiotherapy). Low-risk patients (age < 60 without B-symptoms) had a 5-year OS of 77% (95% CI 67-89%). In the present study of limited-stage nodal PTCL, survival after curative intent chemotherapy +/- radiotherapy was inferior to that of limited-stage diffuse large B-cell lymphoma, but a subgroup of young patients without B-symptoms had very good outcomes. Treatment outcomes after 3-4 cycles versus 6-8 cycles of CHOP(-like) therapy were comparable.
引用
- Ludvigsen Al-Mashhadi A, Cederleuf H, Kuhr Jensen R, et al. Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group. Am J Hematol. 2023. PMID: 36588403. doi:10.1002/ajh.26803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。